# Sotatercept

Drug · id `cardio:sotatercept` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Winrevair; Sotatercept-csrk

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Sotatercept, sold as Winrevair, is an activin signaling inhibitor. The US label lists treating adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization functional class, and to reduce the risk of clinical worsening events. The label describes it as a recombinant activin receptor type IIA-Fc fusion protein. It is filed under the class page for activin signaling inhibitors, of which it is the only member.

## Technical summary

RxNorm ingredient 2678930. The openFDA label record carries no UNII and no substance name, and the Drugs@FDA ingredient string is SOTATERCEPT-CSRK, kept as an alias. MeSH has no descriptor for sotatercept (name lookups on 2026-11-18 found only a supplementary concept term), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class Activin Signaling Inhibitor (and the mechanism class Activin Signaling Inhibitors), with sotatercept as the only member, so the record is filed under the class page for activin signaling inhibitors on that evidence; the Winrevair label also calls it an activin signaling inhibitor. The label read is the Merck Sharp & Dohme LLC label for Winrevair, application BLA761363, effective 2026-09-21 in openFDA. This page records the label indication, the mechanism sentence and the class name only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Adults with pulmonary arterial hypertension, as described in the US label of Winrevair

Recipient: Adult; Population: Adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Winrevair (sotatercept-csrk, Merck Sharp & Dohme LLC, application BLA761363; the version dated 2026-09-21 in openFDA) describes the medicine as an activin signaling inhibitor. It lists treating adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class, and to reduce the risk of clinical worsening events.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Winrevair (sotatercept-csrk for injection), Merck Sharp & Dohme LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 21693ee2-cd23-4137-ac67-066bb3a4a9b7 (manufacturer Merck Sharp & Dohme LLC, application BLA761363), returned on 2026-11-18. The label text is dated 2026-09-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2221693ee2-cd23-4137-ac67-066bb3a4a9b7%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T02:47:46Z. Source state: Current. Version fingerprint: 2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536.
     How it applies: Application number of the label read, BLA761363.
  2. Background: openFDA drug label record for Winrevair (sotatercept-csrk for injection), Merck Sharp & Dohme LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 21693ee2-cd23-4137-ac67-066bb3a4a9b7 (manufacturer Merck Sharp & Dohme LLC, application BLA761363), returned on 2026-11-18. The label text is dated 2026-09-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2221693ee2-cd23-4137-ac67-066bb3a4a9b7%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T02:47:46Z. Source state: Current. Version fingerprint: 2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536.
     How it applies: Effective date of the label text read, 20260921.
  3. Supports: openFDA drug label record for Winrevair (sotatercept-csrk for injection), Merck Sharp & Dohme LLC label: indications and mechanism (Regulator, edition The openFDA drug label record for set id 21693ee2-cd23-4137-ac67-066bb3a4a9b7 (manufacturer Merck Sharp & Dohme LLC, application BLA761363), returned on 2026-11-18. The label text is dated 2026-09-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2221693ee2-cd23-4137-ac67-066bb3a4a9b7%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-19T02:47:46Z. Source state: Current. Version fingerprint: 2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536.
     How it applies: Label passage quoted in the research quote table (Q-K30-SOT-LB-03, Q-K30-SOT-LB-04).

## Connected pages

- Sotatercept is an activin signaling inhibitor (FDA established pharmacologic class in RxClass): Activin signaling inhibitors (`cardio:activin-signaling-inhibitors`)
- FDA label lists pulmonary arterial hypertension in adults, to improve exercise capacity and WHO functional class and to reduce the risk of clinical worsening events, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-winrevair-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: a261e46371eb17d59249d1e9a48b340439b8a3bf26aea1327c01041ab21fa018
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
